At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 45 enrolled
Drug / intervention
Sodium Alginate Double Action Chewable Tablets +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-centred, Randomised, Open Label, Placebo-controlled, Two-period Crossover Study to Evaluate 4-hour Esophageal pH Change in GERD Patients After Administration of Compound Sodium Alginate Double Action Chewable Tablets or Matching Placebo Tablets
In Brief
A Phase 3 clinical trial evaluating Sodium Alginate Double Action Chewable Tablets and Placebo for Gastroesophageal Reflux Disease. Completed, enrolled 45 participants across 1 site.
Detailed Summary
This study is being conducted to assess the effectiveness of the Compound Sodium Alginate Double Action Chewable Tablets compared to placebo on acidic reflux events into the esophagus in patients diagnosed with Gastroesophageal Reflux Disease (GERD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastroesophageal Reflux Disease
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 2013
Enrollment StartJul 2013
Primary CompletionDec 2013
TodayJul 2026
First PostedJun 7, 2013
Enrollment StartJul 2, 2013
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 13.1 years ago
Interventions
Sodium Alginate Double Action Chewable Tabletsdrug
4 tablets as a single dose
Placebodrug
4 tablets as a single dose